These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients.
    Author: Foreman C, Russo P, Davies N, Hissaria P, Proudman S, Hughes T, Limaye V.
    Journal: Intern Med J; 2017 Jan; 47(1):112-115. PubMed ID: 28076913.
    Abstract:
    In South Australia, between 2000 and 2014, 57 patients with idiopathic inflammatory myositis (IIM) were treated with intravenous immunoglobulin (IVIg). We reviewed disease characteristics to determine predictors of response to therapy and IVIg dosing and duration to identify opportunities to rationalise IVIg use. Patients with dermatomyositis/polymyositis had a response rate of 77% and were more likely than inclusion body myositis to respond to therapy. Consideration should be given to the use of the lowest possible dose of IVIg and to the undertaking of trials of cessation of IVIg in patients with stable IIM.
    [Abstract] [Full Text] [Related] [New Search]